CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 184 enrolled
Drug / intervention
NVXT topical +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02933879
NCT02933879Phase 2Completed
CompareCT.gov

A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi- Site Phase 2b Clinical Study to Assess the Efficacy, Safety and Tolerability Patients With Mild to Moderate Onychomycosis

Sun Pharmaceutical Industries, Inc.·interventional·Posted Oct 14, 2016·Updated Dec 20, 2018

In Brief

A Phase 2 clinical trial evaluating NVXT topical and Placebo (Vehicle) Topical for Onychomycosis. Completed, enrolled 184 participants across 1 site.

Detailed Summary

A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi- Site Phase 2b Clinical Study to Assess the Efficacy, Safety and Tolerability of 8-Week Regimens of NVXT topical product in Patients with Mild to Moderate Onychomycosis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOnychomycosis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 14, 2016
Enrollment StartMar 21, 2016
Primary CompletionMar 6, 2018
Study CompletionJun 21, 2018
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 9.7 years ago

Interventions

NVXT topicaldrug

topical treatment

Placebo (Vehicle) Topicaldrug

Placebo (Vehicle) Topical